Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.65 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.60 |
| ▸ | CCR9 | P51686 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 11/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38664558 | 1.00 | MCL1 (0.65) | MCL1GPR35CCR9CCR2ALDH1A1 | |
| SCHEMBL20909819 | 0.88 | CCR9 (0.62) | MCL1GPR35CCR9CCR2ALDH1A1 | |
| SCHEMBL9613337 | 0.83 | GPR35 (0.62) | GPR35CCR9CCR2ALDH1A1POLB | |
| SCHEMBL1553069 | 0.83 | GPR35 (0.67) | GPR35CCR2ALDH1A1POLBCYP1A2 | |
| SCHEMBL7488350 | 0.82 | LMNA (0.52) | MCL1ALDH1A1POLBKDM4E | |
| SCHEMBL700700 | 0.81 | CCR2 (0.65) | GPR35CCR9CCR2ABCB11 | |
| SCHEMBL7378692 | 0.81 | ALDH1A1 (0.65) | MCL1GPR35CCR2ALDH1A1POLB | |
| SCHEMBL3107354 | 0.81 | MCL1 (0.56) | MCL1GPR35CCR9CCR2ABCB11 | |
| SCHEMBL27663338 | 0.81 | CCR2 (0.71) | MCL1GPR35CCR9CCR2ABCB11 | |
| SCHEMBL16814415 | 0.80 | MCL1 (0.46) | MCL1GPR35CCR9ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274661-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2909190-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | F. Hoffmann-La Roche AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014060386-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-24 | — | — | WO | disclosed |
| EP-2722329-A1 | Indol-amide compounds as beta-amyloid inhbitors | F. Hoffmann-La Roche AG (CH) | 2014-04-23 | — | — | EP | disclosed |
| US-8124766-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20090036469-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| WO-2008039882-A1 | A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | SANOFI-AVENTIS U.S. LLC (US) | 2008-04-03 | — | — | WO | disclosed |
| CN-1079396-C | Aromatic amidine derivatives useful as selective thrombin inhibitors | C & C RES LAB (KR) | 2002-02-20 | — | — | CN | disclosed |
| CN-1219932-A | Aromatic amidine derivatives useful as selective thrombin inhibitors | C & C RESEARCH LAB (KR) | 1999-06-16 | — | — | CN | disclosed |
| US-4137313-A | ANTICOAGULANTS, ANTIPHLOGISTIC AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1979-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | MCL1 3229/4885GPR35 1008/4885CCR9 4717/4885 |
| US-20090036469-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR2, PTGDR, PTGER2 | MCL1 4649/4885GPR35 144/4885CCR9 1068/4885 |
| US-20150274661-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | APP, BACE1, IAPP | MCL1 4388/4885GPR35 1272/4885CCR9 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.